The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets
Open accessAbstract
Background: Malaria remains one of the leading causes of morbidity, and mortality in Uganda. A large proportion of malaria symptomatic patients seek healthcare in private sector. However, availability and affordability are major barriers to access to effective treatment. The private sector copayment mechanism in Uganda aims to increase availability and affordability of antimalarial agents. Our study assessed availability, price, and market share of quality assured artemisinin-based combination therapies (QAACTs) in private drug outlets in selected districts during the implementation of copayment mechanism. Methods: This was a cross-sectional survey of anti-malarial agents in private drug outlets in in selected moderate-to-high (Tororo, and Apac districts) and low (Kabale and Mbarara districts) malaria transmission settings. Following the World Health Organization/Health Action International (WHO/HAI) criteria, an audit of the antimalarial agents was done using a checklist to determine availability, price, and market share of QAACTs. Data were entered in Epi-data and analyzed in STATA ver 14.0 at 95% confidence level. Results: A total of twenty-eight (28) private drug outlets (pharmacies and drug shops) were included in the survey. One in seven (20/144: 95%CI: 9.1, 20.6) of the antimalarial agents in private drug outlets were quality assured artemisinin-based combination therapies (QAACT). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine (AQ), 7.3% (9/124) were the only QAACTs present in the drug outlets at the time of the survey. The majority, 86.1%% (124/144) of antimalarial agents present in stock in the drug outlets were artemisinin based. The most common, 38.9% (56/144) ACT in the drug outlets was Dihydroartemisinin-Piperaquine (DHP). Most, 69.4% (100/144) of the antimalarial agents were in high malaria transmission settings. The cost of ACT antimalarial agents is high in the country, USD 1.4 (Artemether-Lumefantrine, AL), USD 2.4 (Dihydroartemisinin-Piperaquine, DP), the first line and second-line agents respectively for treatment of uncomplicated malaria in Uganda. There was a statistically significant difference between the dispensing price of ‘Green leaf’ ACTs (QAACT) and the recommended price (p<0.001). Predictors of availability of QAACT in private drug outlets include pharmacy drug outlet (aPR:0.4; 95%CI: 0.2, 0.9) and dispensing price more than 3000UGX (USD 0.83) (aPR: 0.4, 95%CI: 0.1, 0.51). Conclusion: Quality assured artemisinin-based combination therapies (QAACTs) are not common in private drug outlets in selected districts in Uganda. All the drug outlets had at least one ACT antimalarial agent present on the day of the survey. The dispensing price of QAACTs was significantly higher than the recommended markup price. There is need for awareness creation, surveillance, and monitoring of the implementation of Copayment mechanism in the country.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identifying Key Challenges Facing Healthcare Systems In Africa And Potential Solutions
Oleribe, O. E., Momoh, J., Uzochukwu, B. S., Mbofana, F., Adebiyi, A., Barbera, T., Williams, R., & Taylor Robinson, S. D. (2019) · International Journal of General Medicine · doi:10.2147/ijgm.s223882 · Cited by 685
Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 645
Asua, V., Conrad, M. D., Aydemir, O., Duvalsaint, M., Legac, J., Duarte, E., Tumwebaze, P., Chin, D. M., Cooper, R. A., Yeka, A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa687 · Cited by 203
Self-citationTougher, S., Ye, Y., Amuasi, J. H., Kourgueni, I. A., Thomson, R., Goodman, C., Mann, A. G., Ren, R., Willey, B. A., Adegoke, C. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61732-2 · Cited by 173
Patterns and Predictors of Self-Medication in Northern Uganda
Ocan, M., Bwanga, F., Bbosa, G. S., Bagenda, D., Waako, P., Ogwal-Okeng, J., & Obua, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092323 · Cited by 171 · cited 3×
“Recent studies in Uganda have reported high over-the-counter access of antimalarial agents which coupled with the high cost of ACTs could drive inappropriate use [12, 33].”
Self-citationO'Connell, K. A., Gatakaa, H., Poyer, S., Njogu, J., Evance, I., Munroe, E., Solomon, T., Goodman, C., Hanson, K., Zinsou, C., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-326 · Cited by 159
Sabot, O. J., Mwita, A., Cohen, J. M., Ipuge, Y., Gordon, M., Bishop, D., Odhiambo, M., Ward, L., & Goodman, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006857 · Cited by 105
ACTwatch Group, Tougher, S., Hanson, K., & Goodman, C. A. (2017) · Malaria Journal · doi:10.1186/s12936-017-1814-z · Cited by 67
Epstein, A., Maiteki‐Sebuguzi, C., Namuganga, J. F., Nankabirwa, J. I., Gonahasa, S., Opigo, J., Staedke, S. G., Rutazaana, D., Arinaitwe, E., Kamya, M. R., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000676 · Cited by 59
The ACTwatch project: methods to describe anti-malarial markets in seven countries
Shewchuk, T., O’Connell, K. A., Goodman, C. A., Hanson, K., Chapman, S., & Chavasse, D. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-325 · Cited by 54
Research works printed but not linked: 11
- World Health Organisation, 2022, World malaria report 2022.
- 2023, Ministry of Health. Malaria quarterly report.
- Uganda Bureau of Statistics (UBOS) and ICF, 2018, Uganda Demographic and Health Survey 2016.
- UBOS, 2017, Uganda national household survey 2016/17.
- World Health Organisation., 2008, Medicines strategy 2008–2013.
- Roll Back Malaria, 2011, Updated ACT prices under the Affordable Medicines Facility-malaria 1 March 2011 fact sheet.
- HEPS-Uganda, 2017, Assessing Access to Co-Paid Artemisinin-Based Combination Therapies for Malaria in Uganda.
- Ministry of Health, 2014, The Uganda Malaria Reduction Strategic Plan (2014–2020): accelerated nationwide scale up to achieve universal coverage of cost effective malaria prevention and treatment interventions.
- World Health Organization/Health Action International., 2003, Medicine prices: a new approach to measurement.
- Ministry of Health, 2011, Uganda National Malaria Control Policy.
- World Health Organization, 2015, Guidelines for the treatment of malaria
Cited by
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125
Metadata
- Authors
- Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S.
- Affiliations
- Makerere University (UG)
- Joint Clinical Research Centre (UG)
- Soroti University (UG)
- Corresponding author
- Ocan, Moses
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2024-03-27
- Volume
- 19
- Issue
- 3
- Pages
- e0295198
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC10971760
- OpenAlex
- W4393235030
- Cited by
- 1
- References
- 25
- Citations by year
- 2024: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- EDCTP2 (TMA2019CDF-2662 (Pfkelch13 emergence))
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Keywords
- artemisinin-based combination therapy, antimalarial drug availability, drug pricing, market share, malaria treatment access, artemether-lumefantrine, dihydroartemisinin-piperaquine, artemisinin resistance, quality assurance
- MeSH terms
- Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Cross-Sectional Studies, Humans, Malaria, Uganda, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. https://app.cochat.ai/papers/10.1371/journal.pone.0295198
- The paper
- Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S. (2024). Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. PLOS ONE. https://doi.org/10.1371/journal.pone.0295198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.